C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancerHiroaki Ono, Minoru Tanabe, Yutaro Nakamura et al.|Scientific Reports|2021Cited by 43
RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancerHiroaki Ono, Minoru Tanabe, Yoshiki Murase et al.|International Journal of Oncology|2023Cited by 34
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cellsTomotaka Kato, Minoru Tanabe, Hiroaki Ono et al.|PLoS ONE|2021Cited by 30